Damages in life sciences arbitrations
In “Damages in life sciences arbitrations”, a chapter published in The Guide to Damages in International Arbitration, we explore arbitrated disputes in the...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s life sciences arbitration support is grounded in a comprehensive, insiders’ understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 25 years, we have consulted directly with major life science companies, law firms, and regulatory agencies around the globe. This deep industry knowledge is complemented by our extensive experience in complex litigation. CRA’s involvement has helped our clients solve their most challenging strategic problems and resolve their most contentious disputes.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comIn “Damages in life sciences arbitrations”, a chapter published in The Guide to Damages in International Arbitration, we explore arbitrated disputes in the...
CRA consultants contributed chapters for the fourth edition of The Guide to Damages in International Arbitration published by Global Arbitration Review. The...